Three Hidden Gems Flying Under Every Radar: BLCO, MNKD, and VERV Are Quietly Building Something Special

Everyone's busy arguing about which hyperscaler is spending too much on AI capex. Meanwhile, $BLCO (Bausch + Lomb) is out here posting 9% revenue growth and 59% EBITDA growth, raising full-year guidance, and somehow still trading like a mid-cap stepchild nobody invited to the party. CEO Brent Saunders is running 60+ pipeline programs across cataracts, myopia, dry eye, and contact lenses — secular growth drivers that don't care what oil prices do. With aging populations and screen-addicted kids as its core customer base, this is one of the few businesses where demand literally writes itself.

Then there's $MNKD (MannKind Corporation), maker of Afrezza — the only inhaled insulin on the market. With GLP-1 drugs like Ozempic reshaping metabolic disease treatment and over 1 billion people globally living with diabetes or prediabetes, MannKind's inhalable insulin sits at a fascinating intersection of patient convenience and a massive underserved market. It's tiny, underfollowed, and one solid clinical partnership away from a rerating.

Finally, $VERV (Verve Therapeutics) is doing one-and-done gene editing for cardiovascular disease — literally editing the genome to permanently lower bad cholesterol. One successful trial readout could be the kind of binary catalyst that makes early believers look very, very smart. The crowd is distracted; the setup is clean.